News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PhytoMedical Technologies, Inc. (PYTO.OB) Partners with Renowned Specialty Laboratory Latitude Pharmaceuticals Inc. to Develop an IV Formulation for Its Successfully Tested Anti-Cancer Compound for Glioblastoma


8/5/2009 9:02:42 AM

PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems. “Given LATITUDE’s successful track record in formulation development, we are extremely pleased to have partnered with such an innovative group of experts,” commented PhytoMedical, President, CEO, Greg Wujek. “The development and subsequent testing of the IV Formulation are key components in PhytoMedical’s quest to provide physicians and their patients with an effective treatment option for this most difficult to treat and often deadly form of brain cancer.”

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES